Big pharma catalysts to ring in the new year
Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.
Ror1 delivers its second takeout in five weeks
Boehringer Ingelheim buys NBE-Therapeutics, the second Ror1-focused player to be taken out in just over a month.
AHA 2020 – sotagliflozin wins come too late for Lexicon
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.
Primary omecamtiv win is not enough
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
Esmo 2020 – Kras cools off
A long-awaited update from Amgen’s Kras inhibitor shows waning single-agent efficacy – a situation apparently pre-empted by Mirati.
Boehringer hopes schizophrenia apps will Click into place
Licensing deal could enable bundling of antipsychotics with management technology.
